Skip to content

Application of CalliSpheres@ microspheres drug-eluting bead transarterial chemoembolization followed by 125I seed brachytherapy for liver cancer with type I-II PVTT

Application of CalliSpheres@ microspheres drug-eluting bead transarterial chemoembolization followed by 125I seed brachytherapy for liver cancer with type I-II PVTT

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061945
Enrollment
Unknown
Registered
2022-07-13
Start date
2022-07-10
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic carcinoma

Interventions

Group 1 :

Sponsors

First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The patient's sex is not limited, and the age is 18 to 75 years old; 2. HCC patients who meet the clinical diagnostic criteria of Diagnostic Criteria for Primary Liver Cancer (2019 Edition) or are diagnosed by histopathological or cytological examination; 3. The liver function is Child Pugh A/B; 4. Accompanied by PVTT of type I-II according to Cheng's classification; 5. Tumor volume accounts for <= 40% of the total liver volume; 6. ECOG score 0-1; 7. Alanine aminotransferase and aspartate aminotransferase < 5 times the upper limit of normal value, urea nitrogen and creatinine < 1.5 times the upper limit of normal value, INR < 1.7 or prothrombin time < 4 s; 8. There is a suitable efferent pathway of portal vein.

Exclusion criteria

Exclusion criteria: 1. Diffuse primary liver cancer; 2. The patient has serious comorbidities, such as hypertension, coronary heart disease and mental illness history; 3. Abnormal coagulation function; 4. Renal dysfunction; 5. Severe iodine contrast agent allergy; 6. Pregnant or breastfeeding women, patients with childbearing potential who are unwilling or unable to take effective contraceptive measures; 7. Have a history of mental illness or psychotropic substance abuse; 8. Patients with combined HIV infection; 9. Those who have participated in clinical trials of other experimental drugs or devices.

Design outcomes

Primary

MeasureTime frame
Progression-free survival;

Secondary

MeasureTime frame
Overall survival;Objective response rate;Disease control rate;

Countries

China

Contacts

Public ContactDechao Jiao

First Affiliated Hospital of Zhengzhou University

jiaodechao007@126.com+86 13592583911

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026